Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug [Yahoo! Finance]
Kodiak Sciences Inc (KOD)
Last kodiak sciences inc earnings: 11/12 05:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
The randomised, multi-centre trial will assess the efficacy and safety of tarcocimab tedromer in treatment-naïve DR patients. Patients are being randomised at a 1:1 ratio to receive intravitreal injections of tarcocimab tedromer at baseline, week four, week eight, week 20 and week 44. The proportion of eyes showing an improvement of at least two steps on the Diabetic Retinopathy Severity Scale (DRSS) from baseline at week 48 is the trial's primary endpoint. Further outcome measures will assess the proportion of eyes that develop sight-threatening complications of DR and the proportion of eyes improving by three or more steps on the DRSS from baseline at week 48. Kodiak Sciences aims to finish enrolling subjects in the study by the end of this year. If successful, the trial could help the company secure a marketing authorisation application for tarcocimab tedromer. The GLOW2 trial's study design is similar to that of the previous GLOW1 study, which found an 89% reduction i
Show less
Read more
Impact Snapshot
Event Time:
KOD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KOD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KOD alerts
High impacting Kodiak Sciences Inc news events
Weekly update
A roundup of the hottest topics
KOD
News
- Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences [Yahoo! Finance]Yahoo! Finance
- Kodiak Sciences to Present at Upcoming Investor and Clinical ConferencesPR Newswire
- Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus [Yahoo! Finance]Yahoo! Finance
- Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial ResultsPR Newswire
KOD
Earnings
- 5/15/24 - Beat
KOD
Sec Filings
- 6/13/24 - Form 4
- 6/6/24 - Form 8-K
- 5/15/24 - Form 10-Q
- KOD's page on the SEC website